CellxLife Secures Exclusive License for Dendritic Cell Vaccine Targeting Ovarian Cancer
CellLife notes the licensing agreement builds on their existing proprietary dendritic cell platform, which has demonstrated long-term durability in preventing relapse in pediatric patients with metastatic bone cancer in a Phase I clinical study conducted at leading institutions in Europe
June 16, 2026